ReviewFrontiers in microbiology2018
Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture.
Review in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 160 citations in OpenAlex.
- Continuity of Vaccination Across the Life Course: Poland in Comparison with Selected EU/EEA Countries and the United Kingdom.Vaccines · 2026Review
- Highly efficient intranasal H5N1 vaccine based on a safe vesicular stomatitis virus (VSV) vector.Signal transduction and targeted therapy · 2026Article
- A VSV-vector vaccine simultaneously targeting H5N1 hemagglutinin and matrix protein 2 induces robust neutralizing and ADCC antibody responses and provides full protection against lethal H5N1 infection in a mouse model.Journal of virology · 2026Article
- Molecular mechanisms of immune evasion by host protein glycosylation of a bacterial immunogen used in nucleic acid vaccines.The Journal of biological chemistry · 2026Article
- Article
- Sequential aerosol and oral immunization with a bivalent H9N2/H5N2 vaccine protects against H5N1 and H9N2 avian influenza challenges.NPJ vaccines · 2025Article
- Article
- H5N1 Avian Influenza: A Narrative Review of Scientific Advances and Global Policy Challenges.Viruses · 2025Review
- Enhanced Immunogenicity of Chicken H9N2 Influenza Inactivated Vaccine Through a Novel Dual-Targeting Fusion Protein Strategy.Vaccines · 2025Article
- Targeting Respiratory Viruses: The Efficacy of Intranasal mRNA Vaccination in Generating Protective Mucosal and Systemic Immunity Against Influenza A (H1N1).Influenza and other respiratory viruses · 2025Article
- Article
- Article
- Pandemic preparedness through vaccine development for avian influenza viruses.Human vaccines & immunotherapeutics · 2024Review
- Intranasal influenza-vectored vaccine expressing pneumococcal surface protein A protects against Influenza and Streptococcus pneumoniae infections.NPJ vaccines · 2024Article
- Cyanobacterial and microalgae polymers: antiviral activity and applications.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
- Vaccine optimization for highly pathogenic avian influenza: Assessment of antibody responses and protection for virus-like particle vaccines in chickens.Vaccine: X · 2024Article
- Recombinant Influenza A Viruses Expressing Reporter Genes from the Viral NS Segment.International journal of molecular sciences · 2024Review
- The frequency and function of nucleoprotein-specific CD8Journal of virology · 2024Article
- Article
- Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.NPJ vaccines · 2024Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Influenza virus infections pose a significant threat to public health due to annual seasonal epidemics and occasional pandemics. Influenza is also associated with significant economic losses in animal production. The most effective way to prevent influenza infections is through vaccination. Current vaccine programs rely heavily on the vaccine's ability to stimulate neutralizing antibody responses to the hemagglutinin (HA) protein. One of the biggest challenges to an effective vaccination program lies on the fact that influenza viruses are ever-changing, leading to antigenic drift that results in escape from earlier immune responses. Efforts toward overcoming these challenges aim at improving the strength and/or breadth of the immune response. Novel vaccine technologies, the so-called universal vaccines, focus on stimulating better cross-protection against many or all influenza strains. However, vaccine platforms or manufacturing technologies being tested to improve vaccine efficacy are heterogeneous between different species and/or either tailored for epidemic or pandemic influenza. Here, we discuss current vaccines to protect humans and animals against influenza, highlighting challenges faced to effective and uniform novel vaccination strategies and approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.